Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HS248 in the Treatment of Patients With Advanced Solid Tumors

NCT05759234 is registered in ClinicalTrials.gov with Hanhui Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05759234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HS248 in the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Hanhui Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
November 15, 2022
Completion date
December 31, 2023
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult